Most-Favored-Nation (MFN) drug pricing sounds simple on paper: tie what the U.S. pays for certain drugs to the lowest price available in comparable countries. And the motivation is real. In 2022, U.S. prescription drug prices were 2.78× those in 33 other OECD countries; for brand-name drugs, U.S. prices were nearly 4× higher.
The executive order signed in 2025 revives and expands this approach, directing that certain Medicare drug prices be benchmarked against international reference prices. The policy is intended to reduce what the U.S. government pays and, by extension, what patients pay for drugs covered under affected programs.
For clinicians, the most immediate practical effect will be on treatment decision-making for high-cost drugs. If MFN pricing reduces the cost of certain specialty medications, some prescribing decisions that are currently cost-constrained may become more straightforward. Patients who were previously priced out of a preferred therapy may gain access.
The less certain consequence is what happens to drug availability. Manufacturers facing lower reimbursement may limit distribution, delay U.S. launches, or exit certain market segments. This has been documented in countries with strict reference pricing. The risk is real but difficult to predict in the current regulatory environment.
For prescribers, the practical advice is to monitor which drug classes and specific agents are being included in MFN negotiations, watch for any formulary changes that follow, and stay current on whether preferred treatment options for your patient population are affected.
The policy is still being implemented, and its clinical impact will depend heavily on the specific drugs covered, the pace of rollout, and how manufacturers respond. What is certain is that drug pricing is becoming a more visible part of the prescribing conversation—and clinicians who understand the landscape will be better positioned to guide their patients.